Myriad Genetics
MYGN
272 hedge funds and large institutions have $3.4B invested in Myriad Genetics in 2014 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 82 increasing their positions, 105 reducing their positions, and 48 closing their positions.
2% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 48
1% less funds holding
Funds holding: 275 → 272 (-3)
22% less repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 105
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
47% less call options, than puts
Call options by funds: $30.5M | Put options by funds: $58.2M
48% less capital invested
Capital invested by funds: $6.54B → $3.4B (-$3.14B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$56.9M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$45.6M |
| 3 |
SCM
Sterling Capital Management
Charlotte,
North Carolina
|
+$38M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$24M |
| 5 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$21.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Americafirst Capital Management
Roseville,
California
|
-$2.64B |
| 2 |
RA
Royce & Associates
New York
|
-$136M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
-$75.2M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$13.2M |
| 5 |
GAM
Gotham Asset Management
New York
|
-$10.7M |
MYGN Hedge Fund Activity: Q4 2014 in Review
272 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q4 2014, worth a combined $3.4B — down 48% from $6.54B a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of MYGN and 47 opened new positions — a net loss of 1 holder — while 105 trimmed existing stakes and 82 added.
The largest buyer was Scopia Capital Management, adding an estimated $56.9M. The largest seller was Americafirst Capital Management, exiting entirely with an estimated $2.64B sold.
- 272 institutional investors held Myriad Genetics (MYGN) as of Q4 2014, down from 275 in Q3 2014.
- Funds reported $3.4B of Myriad Genetics stock for Q4 2014, down 48% quarter-over-quarter.
- 47 funds opened new Myriad Genetics positions in Q4 2014 and 48 closed out, a net change of -1 holder.
- The largest Myriad Genetics buyer in Q4 2014 was Scopia Capital Management, an estimated $56.9M added.
- The largest Myriad Genetics seller in Q4 2014 was Americafirst Capital Management, an estimated $2.64B sold.
Based on aggregated 13F filings for Q4 2014.